
Chemical Name : GSK-1120212/GSK1120212/
CAS : 871700-17-3
Synonyms: N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide
Solubility:DMSO
Storage:-20℃ 2 years
Biologieal
An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. MEK inhibitor GSK1120212 specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth. Check for active clinical trials or closed clinical trials using this agent.
3MA/3-methyl-adenin;3-METHYLADENINE;Adenine, 3-methyl-;3-methyladenine,3MA;3-methyl-3H-adenine;3-Methyladenine, pure;6-AMINO-3-METHYLPURINE;3-methyl-3h-purin-6-amin;3-Methyl-3H-purin-6-amine;3-Methyl-6-am
5142-23-4
SB 224289 hydrochloride
180083-23-2
USP25 and 28 inhibitor AZ-3
LDN193189(DM3189)/LDN-193189
1062368-24-4